2018-10-05 Comments Off on FDA Approves Genentech’s Xolair (omalizumab) Prefilled Syringe Formulation FDA Approves Genentech’s Xolair (omalizumab) Prefilled Syringe Formulation South San Francisco, CA — September 28, 2018 — Genentech,
2018-09-17 Comments Off on FDA Approves Subcutaneous Formulation of Actemra for Use in Active Systemic Juvenile Idiopathic Arthritis (SJIA) FDA Approves Subcutaneous Formulation of Actemra for Use in Active Systemic Juvenile Idiopathic Arthritis (SJIA) South San Francisco, CA — September 13, 2018 — Genentech,